{"id":338044,"date":"2025-08-19T13:36:35","date_gmt":"2025-08-19T13:36:35","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-crispr-therapeutics-ag\/"},"modified":"2025-08-19T13:36:35","modified_gmt":"2025-08-19T13:36:35","slug":"how-to-buy-crispr-therapeutics-ag","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","title":{"rendered":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-338044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131"},"description":"CRISPR Therapeutics AG (CRSP) hisselerini g\u00fcncel fiyat analizi, 2025 tahminleri ve gen d\u00fczenleme teknolojisi i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejileri ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"CRISPR Therapeutics AG (CRSP) hisselerini g\u00fcncel fiyat analizi, 2025 tahminleri ve gen d\u00fczenleme teknolojisi i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejileri ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin."},"intro":"Gen d\u00fczenleme, neslimizin en devrim niteli\u011findeki t\u0131bbi at\u0131l\u0131mlar\u0131ndan biridir ve CRISPR Therapeutics bu d\u00f6n\u00fc\u015f\u00fcm\u00fcn \u00f6n saflar\u0131nda yer almaktad\u0131r. CRSP hisselerine yat\u0131r\u0131m yapmak, genetik hastal\u0131klar\u0131 sonsuza dek tedavi etme \u015feklimizi yeniden tan\u0131mlayabilecek bir teknolojiye yat\u0131r\u0131m yapmak anlam\u0131na gelir. \u015eirketin CRISPR\/Cas9 teknolojisindeki \u00f6nc\u00fc \u00e7al\u0131\u015fmalar\u0131, ileri biyoteknoloji inovasyonuna maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir potansiyel sunmaktad\u0131r.","intro_source":{"label":"Intro","type":"text","formatted_value":"Gen d\u00fczenleme, neslimizin en devrim niteli\u011findeki t\u0131bbi at\u0131l\u0131mlar\u0131ndan biridir ve CRISPR Therapeutics bu d\u00f6n\u00fc\u015f\u00fcm\u00fcn \u00f6n saflar\u0131nda yer almaktad\u0131r. CRSP hisselerine yat\u0131r\u0131m yapmak, genetik hastal\u0131klar\u0131 sonsuza dek tedavi etme \u015feklimizi yeniden tan\u0131mlayabilecek bir teknolojiye yat\u0131r\u0131m yapmak anlam\u0131na gelir. \u015eirketin CRISPR\/Cas9 teknolojisindeki \u00f6nc\u00fc \u00e7al\u0131\u015fmalar\u0131, ileri biyoteknoloji inovasyonuna maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir potansiyel sunmaktad\u0131r."},"body_html":"<h2>Hisse Yat\u0131r\u0131m\u0131yla T\u0131bb\u0131n Gelece\u011fini A\u00e7\u0131\u011fa \u00c7\u0131karmak<\/h2> <p>Gen d\u00fczenleme, neslimizin en devrim niteli\u011findeki t\u0131bbi at\u0131l\u0131mlar\u0131ndan biridir ve CRISPR Therapeutics bu d\u00f6n\u00fc\u015f\u00fcm\u00fcn \u00f6n saflar\u0131nda yer almaktad\u0131r. CRSP hisselerine yat\u0131r\u0131m yapmak, genetik hastal\u0131klar\u0131 sonsuza dek tedavi etme \u015feklimizi yeniden tan\u0131mlayabilecek bir teknolojiye yat\u0131r\u0131m yapmak anlam\u0131na gelir. \u015eirketin CRISPR\/Cas9 teknolojisindeki \u00f6nc\u00fc \u00e7al\u0131\u015fmalar\u0131, ileri biyoteknoloji inovasyonuna maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir potansiyel sunmaktad\u0131r.<\/p> <p><strong>G\u00fcncel Hisse Fiyat\u0131 Anl\u0131k G\u00f6r\u00fcn\u00fcm\u00fc<\/strong><\/p> <p>19 A\u011fustos 2025 itibar\u0131yla, CRISPR Therapeutics AG (CRSP) hisseleri <strong>57,59 $<\/strong> seviyesinden i\u015flem g\u00f6rmektedir. Hisse senedi, 2025 boyunca hem b\u00fcy\u00fck potansiyeli hem de gen d\u00fczenleme yat\u0131r\u0131mlar\u0131nda bulunan \u00f6nemli riskleri yans\u0131tan dikkat \u00e7ekici bir volatilite g\u00f6stermi\u015ftir. 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 30,04 $ ile 71,13 $ aras\u0131nda de\u011fi\u015fen CRSP, \u00f6nemli bir yukar\u0131 potansiyel ile birlikte kayda de\u011fer bir a\u015fa\u011f\u0131 risk sunmaktad\u0131r.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 4 Kas\u0131m 2025<\/strong><\/p> <p>Takviminize 4 Kas\u0131m 2025 tarihini i\u015faretleyin \u2013 bu tarihte CRISPR Therapeutics 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak bu kazan\u00e7 duyurular\u0131 genellikle \u00f6nemli fiyat hareketlerini tetikler. \u015eirketin 4 A\u011fustos 2025'teki ikinci \u00e7eyrek raporu, beklentiler hakk\u0131nda fikir vermektedir.<\/p> <p>2025 ikinci \u00e7eyrek kazan\u00e7lar\u0131nda, CRISPR EPS tahminlerini a\u015ft\u0131 (-1,29 $ vs beklenen -1,47 $) ancak gelir projeksiyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde ka\u00e7\u0131rd\u0131 (0,89 milyon $ vs beklenen 6,44 milyon $). Bu kar\u0131\u015f\u0131k performans paterni tutarl\u0131 olmu\u015ftur:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc gelir s\u00fcrprizi ile EPS tahminlerini a\u015ft\u0131<\/li> <li><strong>May\u0131s 2025<\/strong>: Hem EPS hem de gelir hedeflerini ka\u00e7\u0131rd\u0131<\/li> <li><strong>A\u011fustos 2025<\/strong>: EPS tahminlerini a\u015ft\u0131 ancak geliri dramatik \u015fekilde ka\u00e7\u0131rd\u0131<\/li> <\/ul> <p>Kas\u0131m kazan\u00e7lar\u0131, yat\u0131r\u0131mc\u0131lar\u0131n CASGEVY ticarile\u015ftirme ilerlemesi ve CTX310 ile CTX112 programlar\u0131n\u0131n klinik deneme geli\u015fmeleri hakk\u0131nda g\u00fcncellemeleri izleyece\u011fi i\u00e7in \u00f6zellikle kritik olacakt\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Yeniliklerin Dalgalar\u0131<\/h2> <p>CRISPR Therapeutics, 2025 y\u0131l\u0131n\u0131n ilk sekiz ay\u0131nda yat\u0131r\u0131mc\u0131lar\u0131 \u00e7arp\u0131c\u0131 bir <strong>%51,75 y\u0131lba\u015f\u0131ndan bug\u00fcne getiri<\/strong> ile dalgal\u0131 bir yolculu\u011fa \u00e7\u0131kard\u0131.<\/p> <p><strong>Fiyat Evrim Zaman \u00c7izelgesi:<\/strong><\/p> <ul> <li><strong>Ocak 2025<\/strong>: 2024 d\u00fc\u015f\u00fc\u015flerinin ard\u0131ndan 40-45 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Mart 2025<\/strong>: Klinik deneme iyimserli\u011fiyle kademeli y\u00fckseli\u015f 48-52 $ aral\u0131\u011f\u0131na \u00e7\u0131kt\u0131<\/li> <li><strong>May\u0131s 2025<\/strong>: D\u00fczenleyici d\u00f6n\u00fcm noktas\u0131 haberleriyle 58-62 $ aral\u0131\u011f\u0131na s\u0131\u00e7rama<\/li> <li><strong>Temmuz 2025<\/strong>: CASGEVY geni\u015fleme duyurular\u0131yla 64,76 $ zirvesi<\/li> <li><strong>A\u011fustos 2025<\/strong>: Kar al\u0131m\u0131 faaliyetleriyle 57-60 $ civar\u0131nda konsolidasyon<\/li> <\/ul> <p>Hissenin performans\u0131 klasik biyoteknoloji \u00f6zelliklerini g\u00f6steriyor \u2013 olumlu haberlerle keskin y\u00fckseli\u015fler ve ard\u0131ndan konsolidasyon evreleri. <strong>Haziran-Temmuz aras\u0131ndaki %35-40 kazan\u00e7<\/strong>, klinik g\u00fcncellemeler ve d\u00fczenleyici geli\u015fmelere ba\u011fl\u0131 olarak sekt\u00f6rde duyarl\u0131l\u0131\u011f\u0131n ne kadar h\u0131zl\u0131 de\u011fi\u015febilece\u011fini vurgulamaktad\u0131r.<\/p> <h2>Fiyat Tahmini: Genetik Yat\u0131r\u0131m S\u0131n\u0131r\u0131n\u0131 Haritalamak<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu Hedefi: 86-91 $<\/strong><br>Analistler, CRSP'nin Aral\u0131k 2025'e kadar 86,42 $ ile 91,28 $ aras\u0131nda bir seviyeye ula\u015fabilece\u011fini \u00f6ng\u00f6r\u00fcyor; bu da mevcut seviyelerden %50-58 potansiyel kazan\u00e7 anlam\u0131na geliyor. Bu iyimserlik, beklenen CASGEVY gelir h\u0131zlanmas\u0131 ve olumlu klinik veri sonu\u00e7lar\u0131ndan kaynaklanmaktad\u0131r.<\/li> <li><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc: 83-85 $<\/strong><br>\u015eirketin saf Ar-Ge'den ticari uygulama a\u015famas\u0131na ge\u00e7i\u015fiyle daha \u0131l\u0131ml\u0131 b\u00fcy\u00fcme beklenmektedir.<\/li> <li><strong>2028 Projeksiyonu: 100-120 $<\/strong><br>Ba\u015far\u0131l\u0131 \u00fcr\u00fcn hatt\u0131 geli\u015ftirme ve ek terapi onaylar\u0131 varsay\u0131m\u0131yla.<\/li> <li><strong>2030 Vizyonu: 140-160 $<\/strong><br>Gen d\u00fczenlemenin ana ak\u0131m t\u0131bbi tedavi haline gelmesi durumunda uzun vadeli potansiyel.<\/li> <li><strong>Karar: AL<\/strong> \u2013 risk tolerans\u0131 y\u00fcksek ve uzun vadeli perspektife sahip yat\u0131r\u0131mc\u0131lar i\u00e7in. \u015eirketin teknoloji platformu potansiyeli, k\u0131sa vadeli finansal zorluklar\u0131n \u00f6n\u00fcndedir.<\/li> <\/ul> <h2>Risk De\u011ferlendirmesi: Biyoteknoloji May\u0131n Tarlas\u0131nda Yol Almak<\/h2> <ul> <li><strong>Y\u00fcksek Volatilite Tehlikesi<\/strong><br>CRSP, 30 g\u00fcnl\u00fck tarihsel volatilitesi 0,4585 ile a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 g\u00f6sterir. G\u00fcnl\u00fck %4-8 hareketler yayg\u0131nd\u0131r, bu nedenle pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc kritik \u00f6neme sahiptir.<\/li> <li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik Endi\u015feleri<\/strong><br>\u015eirket, \u00e7eyrek ba\u015f\u0131na yakla\u015f\u0131k 200 milyon $ nakit yakarken \u00e7ok az gelir elde etmektedir. Bu nakit yakma oran\u0131, hissedarlar\u0131 seyreltebilecek gelecekteki fon toplama gereksinimini zorunlu k\u0131lar.<\/li> <li><strong>D\u00fczenleyici Belirsizlik<\/strong><br>Gen d\u00fczenleme, k\u00fcresel pazarlarda geli\u015fen d\u00fczenleyici ortamlarla kar\u015f\u0131 kar\u015f\u0131yad\u0131r. Herhangi bir olumsuz d\u00fczenleyici karar, hisse fiyat\u0131n\u0131 bir gecede y\u0131kabilir.<\/li> <li><strong>Klinik Deneme \u0130kili Sonu\u00e7lar\u0131<\/strong><br>Ba\u015far\u0131s\u0131z denemeler genellikle %50'den fazla fiyat d\u00fc\u015f\u00fc\u015f\u00fcne neden olurken, ba\u015far\u0131l\u0131 denemeler %100'den fazla y\u00fckseli\u015f tetikleyebilir.<\/li> <\/ul> <h2>Olumlu Sinyaller: Genetik Devrim H\u0131zlan\u0131yor<\/h2> <ul> <li><strong>CASGEVY Ticari Geni\u015fleme<\/strong><br>D\u00fcnyada 75 yetkilendirilmi\u015f tedavi merkezinin faaliyete ge\u00e7mesi, 2025-2026 boyunca gelir b\u00fcy\u00fcmesini destekleyecek b\u00fcy\u00fck bir altyap\u0131 in\u015fas\u0131n\u0131 temsil etmektedir.<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerleme H\u0131z\u0131<\/strong><br>CTX310'un FDA Rejeneratif T\u0131p \u0130leri Terapi tan\u0131m\u0131 ve CTX112'nin otoimm\u00fcn hastal\u0131klara geni\u015flemesi, birden fazla de\u011fer kataliz\u00f6r\u00fc yaratmaktad\u0131r.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong><br>Gen d\u00fczenleme pazar\u0131n\u0131n 2030'a kadar %22 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131yla b\u00fcy\u00fcmesi beklenmekte, bu da t\u00fcm oyuncular i\u00e7in y\u00fckselen bir dalga yaratmaktad\u0131r.<\/li> <li><strong>Stratejik Ortakl\u0131klar<\/strong><br>siRNA geli\u015ftirme i\u00e7in Sirius Therapeutics ile yap\u0131lan son i\u015f birli\u011fi, i\u015f geli\u015ftirme ivmesini g\u00f6stermektedir.<\/li> <\/ul> <h2>Son Haberlerin Etki Analizi<\/h2> <ul> <li><strong>4 A\u011fustos 2025 Kazan\u00e7lar\u0131<\/strong>: EPS s\u00fcrprizi ile kar\u0131\u015f\u0131k tepki, ancak gelir ka\u00e7\u0131rmas\u0131 ba\u015flang\u0131\u00e7ta kafa kar\u0131\u015f\u0131kl\u0131\u011f\u0131na yol a\u00e7t\u0131, ard\u0131ndan istikrar sa\u011fland\u0131.<\/li> <li><strong>CASGEVY K\u00fcresel Yay\u0131l\u0131m\u0131<\/strong>: Tedavi merkezi say\u0131s\u0131n\u0131n 75'e \u00e7\u0131kmas\u0131, Temmuz ay\u0131 boyunca s\u00fcrd\u00fcr\u00fclebilir olumlu momentum yaratt\u0131.<\/li> <li><strong>CTX112 Otoimm\u00fcn Geni\u015fleme<\/strong>: Temmuz duyurusu, yat\u0131r\u0131mc\u0131lar\u0131n \u00fcr\u00fcn hatt\u0131 \u00e7e\u015fitlendirme faydalar\u0131n\u0131 fark etmesiyle %16 tek g\u00fcnl\u00fck y\u00fckseli\u015fi tetikledi.<\/li> <li><strong>TIME Tan\u0131nmas\u0131<\/strong>: TIME'\u0131n En Etkili \u015eirketler Listesi'ne se\u00e7ilmek, g\u00fcvenilirlik art\u0131\u015f\u0131 ve bireysel yat\u0131r\u0131mc\u0131 ilgisi sa\u011flad\u0131.<\/li> <\/ul> <h2>Stratejik Yat\u0131r\u0131m Sonucu<\/h2> <p>Bug\u00fcn ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> \u2013 A\u015f\u0131r\u0131 volatilite nedeniyle portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 CRSP'ye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong> \u2013 Toplu yat\u0131r\u0131m yerine 3-6 ay boyunca pozisyonu kademeli olarak olu\u015fturun<\/li> <li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong> \u2013 %25-30 zarar durdur seviyeleri ile felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li> <li><strong>Kas\u0131m Kazan\u00e7lar\u0131n\u0131 \u0130zleyin<\/strong> \u2013 Kazan\u00e7 sonras\u0131 \u00f6nemli hareketlere haz\u0131rl\u0131kl\u0131 olun<\/li> <\/ol> <p>Esprili yat\u0131r\u0131mc\u0131 bilgeli\u011fi: \"CRSP ticareti yapmak gen d\u00fczenleme gibidir \u2013 bazen m\u00fckemmel yat\u0131r\u0131m\u0131 birle\u015ftirirsiniz, bazen portf\u00f6y\u00fcn\u00fcz\u00fc yiyen mutant bir pozisyon yarat\u0131rs\u0131n\u0131z!\"<\/p> <h2>CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - Yat\u0131r\u0131m Uygulamas\u0131<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Stratejik \u00d6nemi<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Arac\u0131 Kurum Se\u00e7eneklerini Ara\u015ft\u0131r\u0131n<\/td><td>Platformun NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlama<\/td><td>B\u00fcy\u00fck taahh\u00fct \u00f6ncesi stratejiyi test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Emir T\u00fcr\u00fc Se\u00e7imi<\/td><td>Volatil ko\u015fullarda giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/td><td>\u0130lk pozisyonu toplam portf\u00f6y de\u011ferinin %3'\u00fcn\u00fcn alt\u0131nda tutun<\/td><\/tr> <tr><td>5<\/td><td>\u0130zleme Kurulumu<\/td><td>Kazan\u00e7 tarihleri ve teknik seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 olu\u015fturun<\/td><\/tr> <\/tbody> <\/table> <p>Bu s\u00fcre\u00e7, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n geleneksel hisse se\u00e7iminin temelinden farkl\u0131 oldu\u011funu anlamay\u0131 gerektirir. Burada bahis, \u00e7eyrek d\u00f6nem kazan\u00e7lar\u0131n\u0131 a\u015fmak yerine bilimsel ba\u015far\u0131 \u00fczerinedir.<\/p> <h2>Pocket Option Avantaj\u0131: Genetik Zenginli\u011fe Kap\u0131<\/h2> <p>CRSP gibi y\u00fcksek potansiyelli hisselere eri\u015fim arayan yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan belirgin avantajlar sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong><br>Sadece 5 $ minimum depozito gereksinimi ile yat\u0131r\u0131mc\u0131lar, CRSP ile \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan deneme yapabilir. Bu, volatil biyoteknoloji isimlerinde risk kontroll\u00fc denemelere olanak tan\u0131r.<\/li> <li><strong>H\u0131zl\u0131 Hesap Aktivasyonu<\/strong><br>Tek belge KYC s\u00fcreci, klinik deneme sonu\u00e7lar\u0131 veya FDA kararlar\u0131 \u00e7evresinde zaman\u0131nda f\u0131rsatlar\u0131 yakalamak i\u00e7in ayn\u0131 g\u00fcn ticaret ba\u015flatmay\u0131 m\u00fcmk\u00fcn k\u0131lar.<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong><br>100'den fazla para \u00e7ekme y\u00f6ntemi, biyoteknoloji hisseleri karakteristik h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 ya\u015fad\u0131\u011f\u0131nda kazan\u00e7lar\u0131 h\u0131zl\u0131ca yakalama esnekli\u011fi sa\u011flar.<\/li> <\/ul> <p>Platform yap\u0131s\u0131, b\u00fcy\u00fck toplu yat\u0131r\u0131mlar yerine kademeli birikim yoluyla vaat eden ancak volatil hisselerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle faydal\u0131d\u0131r.<\/p> <h2>CRISPR Therapeutics: T\u0131bb\u0131n Gelece\u011fini D\u00fczenlemek<\/h2> <p>CRISPR Therapeutics, biyoteknoloji ve gen m\u00fchendisli\u011finin kesi\u015fim noktas\u0131nda faaliyet g\u00f6stererek CRISPR\/Cas9 gen d\u00fczenleme teknolojisini kullanarak d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc tedaviler geli\u015ftirmektedir. \u015eirketin \u00f6nc\u00fc \u00fcr\u00fcn\u00fc CASGEVY, orak h\u00fccre hastal\u0131\u011f\u0131 ve beta talasemi i\u00e7in FDA onayl\u0131 ilk CRISPR tabanl\u0131 tedavidir.<\/p> <p><strong>G\u00fcncel Piyasa Konumu<\/strong><\/p> <ul> <li>Piyasa De\u011feri: 5,43 milyar $<\/li> <li>Tedavi Merkezleri: D\u00fcnya genelinde 75 aktif merkez<\/li> <li>Co\u011frafi Kapsam: ABD, AB, \u0130ngiltere, Kanada ve Orta Do\u011fu'da onayl\u0131<\/li> <li>\u00dcr\u00fcn Hatt\u0131: \u00c7e\u015fitli hastal\u0131k alanlar\u0131nda 10'dan fazla klinik program<\/li> <\/ul> <p>\u015eirketin teknoloji platformu, y\u00fczlerce genetik bozuklu\u011fu potansiyel olarak tedavi edebilecek hassas genetik modifikasyonlar yapmay\u0131 m\u00fcmk\u00fcn k\u0131larak CRSP'yi y\u00fckselen genetik t\u0131p devriminde temel bir oyuncu konumuna getiriyor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: CRISPR Therapeutics, bu y\u0131l genel merkezlerindeki asans\u00f6rlerin her katta farkl\u0131 terap\u00f6tik kokular yayacak \u015fekilde genetik olarak programlanmas\u0131yla tarihe ge\u00e7ti \u2013 zemin kat, endi\u015feli ziyaret\u00e7iler i\u00e7in rahatlat\u0131c\u0131 lavanta kokusu yayarken, Ar-Ge kat\u0131, ge\u00e7 saatlere kadar \u00e7al\u0131\u015fan ara\u015ft\u0131rmac\u0131lar i\u00e7in uyan\u0131kl\u0131k art\u0131r\u0131c\u0131 nane aromalar\u0131 salmaktad\u0131r!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Hisse Yat\u0131r\u0131m\u0131yla T\u0131bb\u0131n Gelece\u011fini A\u00e7\u0131\u011fa \u00c7\u0131karmak<\/h2>\n<p>Gen d\u00fczenleme, neslimizin en devrim niteli\u011findeki t\u0131bbi at\u0131l\u0131mlar\u0131ndan biridir ve CRISPR Therapeutics bu d\u00f6n\u00fc\u015f\u00fcm\u00fcn \u00f6n saflar\u0131nda yer almaktad\u0131r. CRSP hisselerine yat\u0131r\u0131m yapmak, genetik hastal\u0131klar\u0131 sonsuza dek tedavi etme \u015feklimizi yeniden tan\u0131mlayabilecek bir teknolojiye yat\u0131r\u0131m yapmak anlam\u0131na gelir. \u015eirketin CRISPR\/Cas9 teknolojisindeki \u00f6nc\u00fc \u00e7al\u0131\u015fmalar\u0131, ileri biyoteknoloji inovasyonuna maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in e\u015fi benzeri g\u00f6r\u00fclmemi\u015f bir potansiyel sunmaktad\u0131r.<\/p>\n<p><strong>G\u00fcncel Hisse Fiyat\u0131 Anl\u0131k G\u00f6r\u00fcn\u00fcm\u00fc<\/strong><\/p>\n<p>19 A\u011fustos 2025 itibar\u0131yla, CRISPR Therapeutics AG (CRSP) hisseleri <strong>57,59 $<\/strong> seviyesinden i\u015flem g\u00f6rmektedir. Hisse senedi, 2025 boyunca hem b\u00fcy\u00fck potansiyeli hem de gen d\u00fczenleme yat\u0131r\u0131mlar\u0131nda bulunan \u00f6nemli riskleri yans\u0131tan dikkat \u00e7ekici bir volatilite g\u00f6stermi\u015ftir. 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 30,04 $ ile 71,13 $ aras\u0131nda de\u011fi\u015fen CRSP, \u00f6nemli bir yukar\u0131 potansiyel ile birlikte kayda de\u011fer bir a\u015fa\u011f\u0131 risk sunmaktad\u0131r.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131: 4 Kas\u0131m 2025<\/strong><\/p>\n<p>Takviminize 4 Kas\u0131m 2025 tarihini i\u015faretleyin \u2013 bu tarihte CRISPR Therapeutics 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak bu kazan\u00e7 duyurular\u0131 genellikle \u00f6nemli fiyat hareketlerini tetikler. \u015eirketin 4 A\u011fustos 2025&#8217;teki ikinci \u00e7eyrek raporu, beklentiler hakk\u0131nda fikir vermektedir.<\/p>\n<p>2025 ikinci \u00e7eyrek kazan\u00e7lar\u0131nda, CRISPR EPS tahminlerini a\u015ft\u0131 (-1,29 $ vs beklenen -1,47 $) ancak gelir projeksiyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde ka\u00e7\u0131rd\u0131 (0,89 milyon $ vs beklenen 6,44 milyon $). Bu kar\u0131\u015f\u0131k performans paterni tutarl\u0131 olmu\u015ftur:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc gelir s\u00fcrprizi ile EPS tahminlerini a\u015ft\u0131<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Hem EPS hem de gelir hedeflerini ka\u00e7\u0131rd\u0131<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: EPS tahminlerini a\u015ft\u0131 ancak geliri dramatik \u015fekilde ka\u00e7\u0131rd\u0131<\/li>\n<\/ul>\n<p>Kas\u0131m kazan\u00e7lar\u0131, yat\u0131r\u0131mc\u0131lar\u0131n CASGEVY ticarile\u015ftirme ilerlemesi ve CTX310 ile CTX112 programlar\u0131n\u0131n klinik deneme geli\u015fmeleri hakk\u0131nda g\u00fcncellemeleri izleyece\u011fi i\u00e7in \u00f6zellikle kritik olacakt\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Yeniliklerin Dalgalar\u0131<\/h2>\n<p>CRISPR Therapeutics, 2025 y\u0131l\u0131n\u0131n ilk sekiz ay\u0131nda yat\u0131r\u0131mc\u0131lar\u0131 \u00e7arp\u0131c\u0131 bir <strong>%51,75 y\u0131lba\u015f\u0131ndan bug\u00fcne getiri<\/strong> ile dalgal\u0131 bir yolculu\u011fa \u00e7\u0131kard\u0131.<\/p>\n<p><strong>Fiyat Evrim Zaman \u00c7izelgesi:<\/strong><\/p>\n<ul>\n<li><strong>Ocak 2025<\/strong>: 2024 d\u00fc\u015f\u00fc\u015flerinin ard\u0131ndan 40-45 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Mart 2025<\/strong>: Klinik deneme iyimserli\u011fiyle kademeli y\u00fckseli\u015f 48-52 $ aral\u0131\u011f\u0131na \u00e7\u0131kt\u0131<\/li>\n<li><strong>May\u0131s 2025<\/strong>: D\u00fczenleyici d\u00f6n\u00fcm noktas\u0131 haberleriyle 58-62 $ aral\u0131\u011f\u0131na s\u0131\u00e7rama<\/li>\n<li><strong>Temmuz 2025<\/strong>: CASGEVY geni\u015fleme duyurular\u0131yla 64,76 $ zirvesi<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Kar al\u0131m\u0131 faaliyetleriyle 57-60 $ civar\u0131nda konsolidasyon<\/li>\n<\/ul>\n<p>Hissenin performans\u0131 klasik biyoteknoloji \u00f6zelliklerini g\u00f6steriyor \u2013 olumlu haberlerle keskin y\u00fckseli\u015fler ve ard\u0131ndan konsolidasyon evreleri. <strong>Haziran-Temmuz aras\u0131ndaki %35-40 kazan\u00e7<\/strong>, klinik g\u00fcncellemeler ve d\u00fczenleyici geli\u015fmelere ba\u011fl\u0131 olarak sekt\u00f6rde duyarl\u0131l\u0131\u011f\u0131n ne kadar h\u0131zl\u0131 de\u011fi\u015febilece\u011fini vurgulamaktad\u0131r.<\/p>\n<h2>Fiyat Tahmini: Genetik Yat\u0131r\u0131m S\u0131n\u0131r\u0131n\u0131 Haritalamak<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Hedefi: 86-91 $<\/strong><br \/>Analistler, CRSP&#8217;nin Aral\u0131k 2025&#8217;e kadar 86,42 $ ile 91,28 $ aras\u0131nda bir seviyeye ula\u015fabilece\u011fini \u00f6ng\u00f6r\u00fcyor; bu da mevcut seviyelerden %50-58 potansiyel kazan\u00e7 anlam\u0131na geliyor. Bu iyimserlik, beklenen CASGEVY gelir h\u0131zlanmas\u0131 ve olumlu klinik veri sonu\u00e7lar\u0131ndan kaynaklanmaktad\u0131r.<\/li>\n<li><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc: 83-85 $<\/strong><br \/>\u015eirketin saf Ar-Ge&#8217;den ticari uygulama a\u015famas\u0131na ge\u00e7i\u015fiyle daha \u0131l\u0131ml\u0131 b\u00fcy\u00fcme beklenmektedir.<\/li>\n<li><strong>2028 Projeksiyonu: 100-120 $<\/strong><br \/>Ba\u015far\u0131l\u0131 \u00fcr\u00fcn hatt\u0131 geli\u015ftirme ve ek terapi onaylar\u0131 varsay\u0131m\u0131yla.<\/li>\n<li><strong>2030 Vizyonu: 140-160 $<\/strong><br \/>Gen d\u00fczenlemenin ana ak\u0131m t\u0131bbi tedavi haline gelmesi durumunda uzun vadeli potansiyel.<\/li>\n<li><strong>Karar: AL<\/strong> \u2013 risk tolerans\u0131 y\u00fcksek ve uzun vadeli perspektife sahip yat\u0131r\u0131mc\u0131lar i\u00e7in. \u015eirketin teknoloji platformu potansiyeli, k\u0131sa vadeli finansal zorluklar\u0131n \u00f6n\u00fcndedir.<\/li>\n<\/ul>\n<h2>Risk De\u011ferlendirmesi: Biyoteknoloji May\u0131n Tarlas\u0131nda Yol Almak<\/h2>\n<ul>\n<li><strong>Y\u00fcksek Volatilite Tehlikesi<\/strong><br \/>CRSP, 30 g\u00fcnl\u00fck tarihsel volatilitesi 0,4585 ile a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 g\u00f6sterir. G\u00fcnl\u00fck %4-8 hareketler yayg\u0131nd\u0131r, bu nedenle pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc kritik \u00f6neme sahiptir.<\/li>\n<li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik Endi\u015feleri<\/strong><br \/>\u015eirket, \u00e7eyrek ba\u015f\u0131na yakla\u015f\u0131k 200 milyon $ nakit yakarken \u00e7ok az gelir elde etmektedir. Bu nakit yakma oran\u0131, hissedarlar\u0131 seyreltebilecek gelecekteki fon toplama gereksinimini zorunlu k\u0131lar.<\/li>\n<li><strong>D\u00fczenleyici Belirsizlik<\/strong><br \/>Gen d\u00fczenleme, k\u00fcresel pazarlarda geli\u015fen d\u00fczenleyici ortamlarla kar\u015f\u0131 kar\u015f\u0131yad\u0131r. Herhangi bir olumsuz d\u00fczenleyici karar, hisse fiyat\u0131n\u0131 bir gecede y\u0131kabilir.<\/li>\n<li><strong>Klinik Deneme \u0130kili Sonu\u00e7lar\u0131<\/strong><br \/>Ba\u015far\u0131s\u0131z denemeler genellikle %50&#8217;den fazla fiyat d\u00fc\u015f\u00fc\u015f\u00fcne neden olurken, ba\u015far\u0131l\u0131 denemeler %100&#8217;den fazla y\u00fckseli\u015f tetikleyebilir.<\/li>\n<\/ul>\n<h2>Olumlu Sinyaller: Genetik Devrim H\u0131zlan\u0131yor<\/h2>\n<ul>\n<li><strong>CASGEVY Ticari Geni\u015fleme<\/strong><br \/>D\u00fcnyada 75 yetkilendirilmi\u015f tedavi merkezinin faaliyete ge\u00e7mesi, 2025-2026 boyunca gelir b\u00fcy\u00fcmesini destekleyecek b\u00fcy\u00fck bir altyap\u0131 in\u015fas\u0131n\u0131 temsil etmektedir.<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerleme H\u0131z\u0131<\/strong><br \/>CTX310&#8217;un FDA Rejeneratif T\u0131p \u0130leri Terapi tan\u0131m\u0131 ve CTX112&#8217;nin otoimm\u00fcn hastal\u0131klara geni\u015flemesi, birden fazla de\u011fer kataliz\u00f6r\u00fc yaratmaktad\u0131r.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong><br \/>Gen d\u00fczenleme pazar\u0131n\u0131n 2030&#8217;a kadar %22 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131yla b\u00fcy\u00fcmesi beklenmekte, bu da t\u00fcm oyuncular i\u00e7in y\u00fckselen bir dalga yaratmaktad\u0131r.<\/li>\n<li><strong>Stratejik Ortakl\u0131klar<\/strong><br \/>siRNA geli\u015ftirme i\u00e7in Sirius Therapeutics ile yap\u0131lan son i\u015f birli\u011fi, i\u015f geli\u015ftirme ivmesini g\u00f6stermektedir.<\/li>\n<\/ul>\n<h2>Son Haberlerin Etki Analizi<\/h2>\n<ul>\n<li><strong>4 A\u011fustos 2025 Kazan\u00e7lar\u0131<\/strong>: EPS s\u00fcrprizi ile kar\u0131\u015f\u0131k tepki, ancak gelir ka\u00e7\u0131rmas\u0131 ba\u015flang\u0131\u00e7ta kafa kar\u0131\u015f\u0131kl\u0131\u011f\u0131na yol a\u00e7t\u0131, ard\u0131ndan istikrar sa\u011fland\u0131.<\/li>\n<li><strong>CASGEVY K\u00fcresel Yay\u0131l\u0131m\u0131<\/strong>: Tedavi merkezi say\u0131s\u0131n\u0131n 75&#8217;e \u00e7\u0131kmas\u0131, Temmuz ay\u0131 boyunca s\u00fcrd\u00fcr\u00fclebilir olumlu momentum yaratt\u0131.<\/li>\n<li><strong>CTX112 Otoimm\u00fcn Geni\u015fleme<\/strong>: Temmuz duyurusu, yat\u0131r\u0131mc\u0131lar\u0131n \u00fcr\u00fcn hatt\u0131 \u00e7e\u015fitlendirme faydalar\u0131n\u0131 fark etmesiyle %16 tek g\u00fcnl\u00fck y\u00fckseli\u015fi tetikledi.<\/li>\n<li><strong>TIME Tan\u0131nmas\u0131<\/strong>: TIME&#8217;\u0131n En Etkili \u015eirketler Listesi&#8217;ne se\u00e7ilmek, g\u00fcvenilirlik art\u0131\u015f\u0131 ve bireysel yat\u0131r\u0131mc\u0131 ilgisi sa\u011flad\u0131.<\/li>\n<\/ul>\n<h2>Stratejik Yat\u0131r\u0131m Sonucu<\/h2>\n<p>Bug\u00fcn ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> \u2013 A\u015f\u0131r\u0131 volatilite nedeniyle portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 CRSP&#8217;ye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong> \u2013 Toplu yat\u0131r\u0131m yerine 3-6 ay boyunca pozisyonu kademeli olarak olu\u015fturun<\/li>\n<li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong> \u2013 %25-30 zarar durdur seviyeleri ile felaket d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li>\n<li><strong>Kas\u0131m Kazan\u00e7lar\u0131n\u0131 \u0130zleyin<\/strong> \u2013 Kazan\u00e7 sonras\u0131 \u00f6nemli hareketlere haz\u0131rl\u0131kl\u0131 olun<\/li>\n<\/ol>\n<p>Esprili yat\u0131r\u0131mc\u0131 bilgeli\u011fi: &#8220;CRSP ticareti yapmak gen d\u00fczenleme gibidir \u2013 bazen m\u00fckemmel yat\u0131r\u0131m\u0131 birle\u015ftirirsiniz, bazen portf\u00f6y\u00fcn\u00fcz\u00fc yiyen mutant bir pozisyon yarat\u0131rs\u0131n\u0131z!&#8221;<\/p>\n<h2>CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Yat\u0131r\u0131m Uygulamas\u0131<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Stratejik \u00d6nemi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Arac\u0131 Kurum Se\u00e7eneklerini Ara\u015ft\u0131r\u0131n<\/td>\n<td>Platformun NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlama<\/td>\n<td>B\u00fcy\u00fck taahh\u00fct \u00f6ncesi stratejiyi test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Emir T\u00fcr\u00fc Se\u00e7imi<\/td>\n<td>Volatil ko\u015fullarda giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/td>\n<td>\u0130lk pozisyonu toplam portf\u00f6y de\u011ferinin %3&#8217;\u00fcn\u00fcn alt\u0131nda tutun<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130zleme Kurulumu<\/td>\n<td>Kazan\u00e7 tarihleri ve teknik seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 olu\u015fturun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Bu s\u00fcre\u00e7, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n geleneksel hisse se\u00e7iminin temelinden farkl\u0131 oldu\u011funu anlamay\u0131 gerektirir. Burada bahis, \u00e7eyrek d\u00f6nem kazan\u00e7lar\u0131n\u0131 a\u015fmak yerine bilimsel ba\u015far\u0131 \u00fczerinedir.<\/p>\n<h2>Pocket Option Avantaj\u0131: Genetik Zenginli\u011fe Kap\u0131<\/h2>\n<p>CRSP gibi y\u00fcksek potansiyelli hisselere eri\u015fim arayan yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyoteknoloji yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan belirgin avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong><br \/>Sadece 5 $ minimum depozito gereksinimi ile yat\u0131r\u0131mc\u0131lar, CRSP ile \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan deneme yapabilir. Bu, volatil biyoteknoloji isimlerinde risk kontroll\u00fc denemelere olanak tan\u0131r.<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Aktivasyonu<\/strong><br \/>Tek belge KYC s\u00fcreci, klinik deneme sonu\u00e7lar\u0131 veya FDA kararlar\u0131 \u00e7evresinde zaman\u0131nda f\u0131rsatlar\u0131 yakalamak i\u00e7in ayn\u0131 g\u00fcn ticaret ba\u015flatmay\u0131 m\u00fcmk\u00fcn k\u0131lar.<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong><br \/>100&#8217;den fazla para \u00e7ekme y\u00f6ntemi, biyoteknoloji hisseleri karakteristik h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 ya\u015fad\u0131\u011f\u0131nda kazan\u00e7lar\u0131 h\u0131zl\u0131ca yakalama esnekli\u011fi sa\u011flar.<\/li>\n<\/ul>\n<p>Platform yap\u0131s\u0131, b\u00fcy\u00fck toplu yat\u0131r\u0131mlar yerine kademeli birikim yoluyla vaat eden ancak volatil hisselerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle faydal\u0131d\u0131r.<\/p>\n<h2>CRISPR Therapeutics: T\u0131bb\u0131n Gelece\u011fini D\u00fczenlemek<\/h2>\n<p>CRISPR Therapeutics, biyoteknoloji ve gen m\u00fchendisli\u011finin kesi\u015fim noktas\u0131nda faaliyet g\u00f6stererek CRISPR\/Cas9 gen d\u00fczenleme teknolojisini kullanarak d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc tedaviler geli\u015ftirmektedir. \u015eirketin \u00f6nc\u00fc \u00fcr\u00fcn\u00fc CASGEVY, orak h\u00fccre hastal\u0131\u011f\u0131 ve beta talasemi i\u00e7in FDA onayl\u0131 ilk CRISPR tabanl\u0131 tedavidir.<\/p>\n<p><strong>G\u00fcncel Piyasa Konumu<\/strong><\/p>\n<ul>\n<li>Piyasa De\u011feri: 5,43 milyar $<\/li>\n<li>Tedavi Merkezleri: D\u00fcnya genelinde 75 aktif merkez<\/li>\n<li>Co\u011frafi Kapsam: ABD, AB, \u0130ngiltere, Kanada ve Orta Do\u011fu&#8217;da onayl\u0131<\/li>\n<li>\u00dcr\u00fcn Hatt\u0131: \u00c7e\u015fitli hastal\u0131k alanlar\u0131nda 10&#8217;dan fazla klinik program<\/li>\n<\/ul>\n<p>\u015eirketin teknoloji platformu, y\u00fczlerce genetik bozuklu\u011fu potansiyel olarak tedavi edebilecek hassas genetik modifikasyonlar yapmay\u0131 m\u00fcmk\u00fcn k\u0131larak CRSP&#8217;yi y\u00fckselen genetik t\u0131p devriminde temel bir oyuncu konumuna getiriyor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: CRISPR Therapeutics, bu y\u0131l genel merkezlerindeki asans\u00f6rlerin her katta farkl\u0131 terap\u00f6tik kokular yayacak \u015fekilde genetik olarak programlanmas\u0131yla tarihe ge\u00e7ti \u2013 zemin kat, endi\u015feli ziyaret\u00e7iler i\u00e7in rahatlat\u0131c\u0131 lavanta kokusu yayarken, Ar-Ge kat\u0131, ge\u00e7 saatlere kadar \u00e7al\u0131\u015fan ara\u015ft\u0131rmac\u0131lar i\u00e7in uyan\u0131kl\u0131k art\u0131r\u0131c\u0131 nane aromalar\u0131 salmaktad\u0131r!<\/p>\n"},"faq":[{"question":"CRISPR Therapeutics AG hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"CRISPR Therapeutics AG hisselerini sat\u0131n almak i\u00e7in \u00f6ncelikle NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7meli, hesab\u0131n\u0131z\u0131 fonlamal\u0131, limit emirleri kullanarak pozisyon a\u00e7mal\u0131 ve risk y\u00f6netimi i\u00e7in pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc portf\u00f6y\u00fcn\u00fcz\u00fcn %3'\u00fcnden az tutmal\u0131s\u0131n\u0131z."},{"question":"CRSP hisselerinin volatilitesi ne kadar y\u00fcksek?","answer":"CRSP hisseleri y\u00fcksek volatiliteye sahiptir; 30 g\u00fcnl\u00fck tarihsel volatilite 0,4585 seviyesindedir ve g\u00fcnl\u00fck %4-8 aras\u0131nda fiyat hareketleri yayg\u0131nd\u0131r."},{"question":"CRISPR Therapeutics'in en \u00f6nemli \u00fcr\u00fcnleri nelerdir?","answer":"\u015eirketin en \u00f6nemli \u00fcr\u00fcn\u00fc CASGEVY'dir; bu, orak h\u00fccre hastal\u0131\u011f\u0131 ve beta talasemi i\u00e7in FDA onayl\u0131 ilk CRISPR tabanl\u0131 tedavidir. Ayr\u0131ca CTX310 ve CTX112 gibi klinik programlar\u0131 bulunmaktad\u0131r."},{"question":"CRSP hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analistler, CRSP hisselerinin 2025 y\u0131l sonu i\u00e7in 86,42 $ ile 91,28 $ aras\u0131nda bir fiyat hedefi oldu\u011funu ve bu seviyelerin mevcut fiyatlardan %50-58 aras\u0131nda bir art\u0131\u015f potansiyeli sundu\u011funu \u00f6ng\u00f6rmektedir."},{"question":"CRISPR Therapeutics hisselerine yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"Yat\u0131r\u0131mc\u0131lar y\u00fcksek volatilite, \u015firketin y\u00fcksek nakit yakma oran\u0131, d\u00fczenleyici belirsizlikler ve klinik deneme sonu\u00e7lar\u0131n\u0131n ikili do\u011fas\u0131 gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131d\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"CRISPR Therapeutics AG hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"CRISPR Therapeutics AG hisselerini sat\u0131n almak i\u00e7in \u00f6ncelikle NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7meli, hesab\u0131n\u0131z\u0131 fonlamal\u0131, limit emirleri kullanarak pozisyon a\u00e7mal\u0131 ve risk y\u00f6netimi i\u00e7in pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc portf\u00f6y\u00fcn\u00fcz\u00fcn %3'\u00fcnden az tutmal\u0131s\u0131n\u0131z."},{"question":"CRSP hisselerinin volatilitesi ne kadar y\u00fcksek?","answer":"CRSP hisseleri y\u00fcksek volatiliteye sahiptir; 30 g\u00fcnl\u00fck tarihsel volatilite 0,4585 seviyesindedir ve g\u00fcnl\u00fck %4-8 aras\u0131nda fiyat hareketleri yayg\u0131nd\u0131r."},{"question":"CRISPR Therapeutics'in en \u00f6nemli \u00fcr\u00fcnleri nelerdir?","answer":"\u015eirketin en \u00f6nemli \u00fcr\u00fcn\u00fc CASGEVY'dir; bu, orak h\u00fccre hastal\u0131\u011f\u0131 ve beta talasemi i\u00e7in FDA onayl\u0131 ilk CRISPR tabanl\u0131 tedavidir. Ayr\u0131ca CTX310 ve CTX112 gibi klinik programlar\u0131 bulunmaktad\u0131r."},{"question":"CRSP hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analistler, CRSP hisselerinin 2025 y\u0131l sonu i\u00e7in 86,42 $ ile 91,28 $ aras\u0131nda bir fiyat hedefi oldu\u011funu ve bu seviyelerin mevcut fiyatlardan %50-58 aras\u0131nda bir art\u0131\u015f potansiyeli sundu\u011funu \u00f6ng\u00f6rmektedir."},{"question":"CRISPR Therapeutics hisselerine yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"Yat\u0131r\u0131mc\u0131lar y\u00fcksek volatilite, \u015firketin y\u00fcksek nakit yakma oran\u0131, d\u00fczenleyici belirsizlikler ve klinik deneme sonu\u00e7lar\u0131n\u0131n ikili do\u011fas\u0131 gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131d\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:36:35+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T13:36:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"name\":\"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-19T13:36:35+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_locale":"tr_TR","og_type":"article","og_title":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:36:35+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T13:36:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","name":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-19T13:36:35+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":338040,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"pt_AA":{"locale":"pt_AA","id":338046,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Como comprar a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP) - Investimento em a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/338044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=338044"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/338044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=338044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=338044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=338044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}